Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Clinical trial NCT06357676 · RECRUITING
Trial details
- NCT number
- NCT06357676
- Sponsor
- OHSU Knight Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-29
- Primary completion
- 2027-11-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.